產品詳情
簡單介紹:
IRDye800CWRGDOpticalProbe
詳情介紹:
Brand | BrightSite? |
Specificity | Integrin receptors |
Characteristics |
IRDye 800CW RGD Optical Probe is a BrightSite near-infrared (NIR) fluorescently-labeled RGD imaging agent specifically designed to target the overexpression of integrins on tumors. Integrins are cell surgace heterodimeric glycoproteins involved in cell-to-cell and cell-to-matrix interactions. The recognition motif, RGD (Arg-Gly-Asp), is a tripeptide sequence used to bind integrin receptors including ?v?3. Interest in using a labeled RGD peptide ligand for studying and/or monitoring diseases related to ?v?3 receptor over-expression is increasing. IRDye 800CW RGD has been characterized for in vitro and in vivo use with a number of tumor cell lines including U87, A431, PC3M-LN4, and 22Rv1. tripeptide sequence Optical Probe Upon receipt, immediately store at -20 °C prior to reconstitution. When stored properly, this product is stable in the lyophilized state for up to 3 months. After reconstitution, store at 4 °C for a maximum of 1 moth. Protect from light. |
Purification | 0.2 μm nylon membrane |
Application Notes | in vivo: 1 nmol per mouse (25 grams) |
Restrictions | For Research Use only |
Format | Lyophilized |
Reconstitution | Reconstitute with 0.5?mL sterile 1X PBS |
Concentration | 0.01 nM/μL |
Buffer | PBS |
Handling Advice | Protect from light. |
Storage | -20 °C |
Product cited in: |
Huang, Vider, Kovar, Olive, Mellinghoff, Mayer-Kuckuk, Kircher, Blasberg: "Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 18, Issue 20, pp. 5731-40, 2012 (PubMed).
|